3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Timothy J. Iveson, Rachel S. Kerr, Mark P. Saunders, Jim Cassidy, Niels Henrik Hollander, Josep Tabernero, Andrew Haydon, Bengt Glimelius, Andrea Harkin, Karen Allan, John McQueen, Claire Scudder, Kathleen Anne Boyd, Andrew Briggs, Ashita Waterston, Louise Medley, Charles Wilson, Richard Ellis, Sharadah Essapen, Amandeep S. DhaddaMark Harrison, Stephen Falk, Sherif Raouf, Charlotte Rees, Rene K. Olesen, David Propper, John Bridgewater, Ashraf Azzabi, David Farrugia, Andrew Webb, David Cunningham, Tamas Hickish, Andrew Weaver, Simon Gollins, Harpreet S. Wasan, James Paul

Research output: Contribution to journalArticleResearchpeer-review

66 Citations (Scopus)

Fingerprint Dive into the research topics of '3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial'. Together they form a unique fingerprint.

Medicine & Life Sciences